New drug shows promise for Long-Term control of rare muscle disease
NCT ID NCT05332210
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This study looked at the long-term safety of a drug called HBM9161 for people with generalized myasthenia gravis, a condition that causes muscle weakness. Over 100 patients who had already completed an earlier study received the drug as a shot under the skin. Researchers tracked side effects and checked if symptoms improved over 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.